Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Histone Deacetylase Inhibitor, MS-275 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Histone Deacetylase Inhibitor, 3 mg | EXPERIMENTAL | Subjects received 3 mg MS-275 orally biweekly (Days 1 and 15 of a 4 week cycle) or until disease progression or unacceptable toxicity |
| Histone Deacetylase Inhibitor, 7 mg | EXPERIMENTAL | Subjects received 7 mg MS-275 orally weekly (Days 1, 8, and 15 of a 4 week cycle) until disease progression or unacceptable toxicity |
| Name | Type | Description |
|---|---|---|
| Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894) | DRUG | MS-275, 3 mg on Days 1 and 15 of a 4-week cycle |
Inclusion Criteria: * Adult subjects with Stage III or IV non-resectable nonuveal (cutaneous or mucosal) metastatic melanoma who had received at least one but no more than two previous systemic therapies (immunotherapy and/or chemotherapy) for metastatic disease and who had not responded to or who ...
Top 20 of 48 competitors
Histone Deacetylase Inhibitor, MS-275 is an investigational small molecule being studied for the treatment of melanoma, a form of skin cancer. It was evaluated in a Phase 2 trial in patients with metastatic melanoma. It is not an approved therapy and remains in clinical development.
Histone Deacetylase Inhibitor, MS-275 is developed by Bayer AG, which trades on the OTC market under the ticker BAYRY. Bayer sponsored the clinical research evaluating this agent in metastatic melanoma.
Histone Deacetylase Inhibitor, MS-275 is in Phase 2 development. One Phase 2 trial has been completed, and no trials are currently active. The drug is investigational and has not been approved for any indication.
Histone Deacetylase Inhibitor, MS-275 was studied in the completed Phase 2 trial NCT00185302, titled Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma. The trial enrolled 28 patients aged 18 years and older and used a controlled, randomized design without double blinding.
Yes. Histone Deacetylase Inhibitor, MS-275 is also known as BAY 86-5274 and ZK 244894. These are alternative names for the same investigational small molecule developed by Bayer AG for melanoma.